ClinicalTrials.Veeva

Menu

Effect of TECAR (Transfer of Energy Capacitive and Resistive) Therapy on Chronic Supraspinatus Tendinitis

Cairo University (CU) logo

Cairo University (CU)

Status

Not yet enrolling

Conditions

Supraspinatus Tendinitis

Treatments

Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy
Other: Conventional treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT07316712
P.T.REC/012/005900

Details and patient eligibility

About

This study aims to investigate the effect of TECAR therapy on pain, shoulder range of motion, functional disability, and handgrip strength in patients with grade II supraspinatus tendinitis.

Full description

Tendinopathy occurs when pain arises in a tendon near its origin or insertion due to repetitive activities and reduced functional levels. It happens when the tendon does not properly heal. Thirty percent of tendinopathies related to musculoskeletal conditions are associated with shoulder pain, and supraspinatus tendinitis is the third most prevalent problem.

The supraspinatus tendon, part of the rotator cuff of the shoulder joint, is particularly affected. Aging is also a common factor leading to supraspinatus tendon injuries. The primary function of the supraspinatus muscle is shoulder abduction, particularly during movements that elevate the arm overhead. During these motions, the supraspinatus tendon repeatedly passes beneath the acromion process of the scapula, which can result in impingement and subsequent inflammation. An unexpected force or trauma may cause a partial or complete tendon rupture if this condition progresses.

Transfer of Energy Capacitive and Resistive (TECAR) offers a unique variety of treatments for chronic and acute pathologies, with contraindications such as pregnancy, pacemakers, and sensitivity to high temperatures. It should be noted that this new technology is a valuable tool in treating various pathologies, particularly when compared with other therapies in terms of the presence and/or absence of specific positive effects. TECAR also has distinct characteristics that are effective even when other treatments fail. This therapy balances the therapist's manual skills and the specialized energy that this technology offers, resulting in increasingly satisfactory outcomes for therapists and patients.

Enrollment

46 estimated patients

Sex

All

Ages

30 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Supraspinatus Tendinitis grade II based on Neer's classification, confirmed by special tests, signs, and symptoms of grade I and II Supraspinatus Tendinitis for the past month, and taking non-steroidal anti-inflammatory drugs as suggested by the physician.
  • All patients will have a body mass index between 18.5 and 29.9 kg/m².

Exclusion criteria

  • Other grades of Supraspinatus Tendinitis.
  • Any past shoulder surgical interventions.
  • Instability of the shoulder joint due to other reasons, Acromioclavicular Joint Arthritis.
  • Non-cooperative subjects.
  • Diabetes
  • Pregnant or lactating women.
  • Serious neuromuscular or cardiovascular diseases.
  • Systemic illness and severe COVID-19 cases will be excluded from this study.
  • Pacemakers
  • Heat Sensitivity
  • Metal Implants

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

46 participants in 2 patient groups

Conventional treatment + TECAR therapy
Experimental group
Description:
The experimental group will receive conventional physiotherapy sessions as the active comparator group, in addition to TECAR therapy at the end of each session. Sessions will be received for three weeks (nine sessions, three times per week).
Treatment:
Other: Conventional treatment
Device: TECAR (Transfer of Energy Capacitive and Resistive) Therapy
Conventional treatment
Active Comparator group
Description:
The active comparator group will receive conventional physiotherapy sessions for three weeks (nine sessions, three times per week).
Treatment:
Other: Conventional treatment

Trial contacts and locations

1

Loading...

Central trial contact

Mohamed Gamal Ibrahem Alghamry, B.Sc; Hend Hamdy Mohamed Ahmed, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems